WFDC2 and ovarian carcinoma: Given the possible risk of developing gynecologic cancers, particularly endometrium and ovarian cancer, in patients with PCOS, in this study, we examined whether HE4, which has a diagnostic value for ovarian cancer, can be used as a potential diagnostic biomarker for PCOS and is an alarming indicator of ovarian cancer risk in those patients.